News Hub | News Direct

Award-Winning Hair Care Brand Design Essentials Pledges $2 Million to Support Historically Black Colleges and Universities

Design Essentials

Design Essentials, the Atlanta-based Black-owned company leading in premium hair care for nearly 35 years, is proud to contribute $1 million dollars to Spelman College in Atlanta towards the launch of their Cosmetic Science Program, and $1 million dollars to Howard University in Washington D.C. for the creation of The Design Essentials Community Fund. As part of its continued commitment to consumers and future leaders, Design Essentials is leveraging its expertise in healthy haircare practices for all hair types to inspire and give back to the next generation of leaders and innovators. The pledges reflect the brands belief in philanthropy through donations and resources to local and international communities. Design Essentials aims to make a meaningful impact through give-back initiatives focused on community enrichment, education and mentorship, while also serving its professional and consumer network. Improving access to resources that cater to Black women and men for career advancement, the brand is continuing to create inclusive and diverse spaces, along with premium expert-backed products for textured hair. Spelman College is a global leader in the education of women of African descent. The partnership will directly contribute to Spelman’s Cosmetic Science Program – the first-ever major of its kind available at an HBCU (Historically Black College and University). The groundbreaking STEM program offers a culturally relevant approach with unique perspectives from Black women through research and working knowledge of trends and innovations, students will explore the use of cosmetics and personal care products, particularly in communities of African descent. The pledge will impact the innovative research and development of products, connecting future chemists with the core consumer to achieve efficacy and representation in the products they use. Howard University is one of the leading research universities dedicated to educating students from diverse backgrounds. The launch of The Design Essentials Community Fund will pave the way for Howard University School of Business students who aspire to become entrepreneurs and business leaders. Cornell McBride, Jr., President of McBride Research Laboratories, Inc. and a Howard University alumna, credits his business acumen to the success of flagship brand Design Essentials over the past two decades. Students will gain access to business training programs, including business pitch competitions, business plan advisory services, marketing and branding bootcamps, capital-raising modules, and opportunities to learn about new software and technology. “We are incredibly honored to support the future leaders at these HBCUs during this moment in history,” states Cornell McBride Jr., President and Chief Executive Officer of McBride Research Laboratories. As a Howard University alum, McBride Jr. is dedicated to keeping the Design Essentials legacy intact by supporting rising leaders in business and beauty industries. “It has always been our mission to create high-quality products that meet the demand of hairstyling needs, leave a footprint in social impact initiatives, and nurture individuals and scholars who will drive inclusion within the beauty industry. By investing in the first-ever cosmetic science program and ongoing entrepreneurial mentorship and career opportunities, we are reinforcing our commitment to education and ensuring that diverse voices are at the forefront of innovation in our industry.” Design Essentials’ pledge marks the start of a broader effort to support HBCUs at a national level and nurture the connection between multicultural haircare and consumers globally. As a legacy brand, Design Essentials serves as a partner in style, fostering relationships with future leaders and brand fans to achieve styling success. For more information on Design Essentials, please visit www.designessentials.com For additional information on Spelman College’s Cosmetics Science Program, please visit https://www.spelman.edu/academics/cosmetic-science/index.html For more information on Howard University, please visit https://howard.edu/ About Design Essentials Design Essentials is a leading provider of premium hair care solutions with nearly 35 years of experience. The brand offers over 80 curated products for all hair types and textures and is committed to delivering innovative, research-driven solutions that cater to both professional and consumer needs. Design Essentials is proud to be minority-owned and operated, with a global reach and a strong commitment to giving back to communities worldwide. Contact Details First and Last PR Camille Gordon camille@firstandlastpr.com First and Last PR Brooke Bhola brooke@firstandlastpr.com Company Website https://designessentials.com/

October 03, 2024 08:00 AM Eastern Daylight Time

Image

Kevel Named to Newsweek’s List of The Top 200 America’s Most Loved Workplaces for 2024

Kevel

Newsweek Magazine today published the annual America’s Top Most Loved Workplaces® list, developed by Most Loved Workplace®, a division of Best Practice Institute (BPI). Kevel has been honored with a place in the top 20, being ranked # 18 out of the 200 companies included in the list. This marks the fourth annual Most Loved Workplace® list. This year, the list has expanded to the Top 200, reflecting companies' growing commitment to prioritizing employee sentiment and creating workplaces that employees love. The results were determined after surveying more than 2.6 million employees from businesses with workforces varying in size from less than 50 to more than 10,000. The list recognizes companies that put respect, caring, and appreciation for their employees at the center of their business model and, in doing so, have earned the loyalty and respect of the people who work for them. “We are so proud about our inclusion on the Most Loved Workplace® list,” said Mike Kohn, Chief People Officer at Kevel. “We have focused on building a people-first organization since our founding, and have used our values as a north star as we scaled our company. We routinely use engagement surveys and qualitative check-ins both to keep a pulse on how we are working as well as to identify trends and insights that enable us to drive actions in support of building a workplace where everyone can thrive.” How positive workers feel about their future at the company, career achievement, how much employer values align with employee values, respect at all levels, and the level of collaboration at the firm were the five critical areas measured to gauge employee sentiment. In addition, areas such as inclusion, diversity, equity and belonging, career development, and company leadership were identified and analyzed in relation to the five critical areas measured. “It’s inspiring to see the list expand this year to 200 companies, a clear indication that organizations are truly committed to creating workplaces where employees feel valued and connected. We’re thrilled to celebrate their achievements as this recognition continues to grow.” - Nancy Cooper, Newsweek’s Global Editor in Chief To view Kevel’s ranking and the top honored companies view the Top 20 Most Loved Workplaces in America or view the full list of the 2024 America’s Top 200 Most Loved Workplaces®. About Kevel Kevel powers world-class retail media networks with the Retail Media Cloud™. With the combination of the Kevel Ad Server and Kevel Audience, multi-brand retailers, marketplaces, and ecommerce companies can launch limitless ad formats and unique targeting segments online and in-store, all with closed-loop attribution. Kevel believes that every digital retailer should have the capability to scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Klarna, Delivery Hero, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media network with Kevel. The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com. About Newsweek Newsweek is the modern global digital news organization built around the iconic, over 90-year-old American magazine. Newsweek reaches 100 million people each month with its thought-provoking news, opinion, images, graphics, and video delivered across a dozen print and digital platforms. Headquartered in New York City, Newsweek also publishes international editions in EMEA and Asia. About Best Practice Institute Best Practice Institute is an award-winning leadership and organization development center, benchmark research company, think tank, and solutions provider. BPI is the only certifying body for Most Loved Workplace® and conducted the original research to create the model and criteria for becoming a Most Loved Workplace®. BPI’s research proves that Most Loved Workplaces® produce 3-4 times better customer service, employee performance, and retention than companies not loved by their employees. For more information on how to apply to become a certified Most Loved Workplace, go to: http://www.mostlovedworkplace.com Contact Details Kevel Jennifer Choo Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 02, 2024 10:00 AM Eastern Daylight Time

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

COLORESCIENCE® INTRODUCES TOTAL LASH™ MASCARA

Colorescience

Colorescience®, a leading dermatologist-recommended specialty skincare company, is launching Total Lash™ Mascara, an innovative, new all-in-one lash serum, conditioner and mascara that immediately enhances the appearance of lash length and volume for a vibrant, eye-opening effect. With every application, this clinically tested formula works to improve lash health with a blend of peptides and botanicals that nourishes the lashes while helping support the natural lash cycle for healthier, stronger, fuller and longer looking lashes. The Total Lash™ ingredient complex uses gentle, prostaglandin analogue-free ingredients and has been ophthalmology tested and confirmed to be safe for sensitive eyes and contact lens wearers. This formula is ideal for those who want to restore and improve their natural lashes, especially after discontinuing lash extensions, false lashes, or other lash procedures. Dr.Tanya Khan, Oculoplastic Surgeon and Board-Certified Ophthalmologist, led the clinical study. After a 12-week clinical trial with daily usage of Total Lash Mascara 90% of subjects reported their lashes looked longer. As measured by Dr. Khan, lashes were on average 24% longer compared to baseline. Over 92% of subjects reported less lash breakage and 94% reported lashes appeared fuller, thicker, and fluffier after twelve weeks of usage. Recalling these results, Dr. Khan shared, “During the clinical study, it became clear to me that patients were readily achieving their desired results of lash growth, density, thickness, and darkness when using the Total Lash™ product once per day. As an oculoplastic surgeon and ophthalmologist, I am even more amazed that the formula is well-tolerated by sensitive eyes and does not cause irritation or discoloration of the delicate skin around the eye area. I look forward to offering this product to my patients as a safe, effective, and gentle daily option that delivers lash enhancement without prostaglandins or extensions.” This multi-benefit formula enhances the appearance of length and volume, nourishes and strengthens the lashes and supports lash growth. Proven peptide Myristoyl Pentapeptide-17 stimulates the hair follicle to help support continued growth while botanical extracts optimize root health and help promote continued growth for longer, fuller looking lashes. The results are a visibly denser, more defined lash line and longer lashes that are hydrated and nourished. Panthenol and jojoba seed oil condition and nourish lashes to reduce breakage helping strengthen and prolong length and volume. Lastly, the formula immediately enhances lashes upon application while providing all-day smudge-free wear. This tubing mascara wraps each lash in a rich black iron oxide mineral pigment, making this dye-free formula ideal for sensitive eyes. Patricia Boland, VP of Research & Development at Colorescience says, “We created this formula with the tubing feature because our goal is always to treat and improve while delivering immediate enhancement and optimal wear. The skin around the eyes is especially thin and delicate, so extensive rubbing during removal of products can contribute to irritation. Instead, our Total Lash Mascara envelops each lash with our clinically proven treatment complex while maximizing wear-time, and the product removes effortlessly with warm water and a favorite cleanser.” ABOUT COLORESCIENCE Colorescience ®, the leading innovator in all-mineral sun protection, delivers transformational skincare solutions through wearable multifunctional products that provide immediate confidence and long-term visible results. Crafted for users who know that great results require daily skincare and protection, Colorescience ® uses cutting-edge technology and clinically tested formulas to ensure efficacy and provide reassurance to people of all ages, skin types, and concerns. Colorescience ® products speak for themselves through their wearability, published clinical studies, and skin-healthy ingredients. For more information please contact: Project MM, meredith@projectmmnyc.com Contact Details Meredith Winfrey meredith@projectmmnyc.com Company Website https://www.colorescience.com

October 01, 2024 08:00 AM Eastern Daylight Time

Xtreme Trucking Selects HOPTEK’s Dispatch Engine® Solution for Real-Time Visibility and Optimization of Fleet Operations

Hoptek

HOPTEK, a global leader in AI-driven trucking and fleet transportation solutions, has been selected by Xtreme Trucking of Wisconsin, one of the U.S.’s leading technology-first transportation and logistics providers, for its Dispatch Engine® solution, a digital platform providing instant visibility and access to the spot load market, while matching available carrier capacity across thousands of possible options. HOPTEK’s “digital twin” will provide real-time visibility and enable Xtreme to boost operational efficiency and fleet utilization, while reducing driver turnover and deadhead miles, resulting in material cost savings and profitability. Started as a small independent operation in 2006, Xtreme Trucking was formally established in 2009 to become a quality diversified transportation provider, with a growing revenue profile and extensive coverage across the United States. Through HOPTEK’s Dispatch Engine®, Xtreme has leveraged real-time data visibility and dynamic decision-making to drive operational velocity to achieve up to a 20% increase in both Revenue per Hour and Weekly Revenue Miles per Driver – a clear competitive advantage. Travis Nelson, President and Founder of Xtreme Trucking said: “Between supply chain complications, market shifts, and driver shortages, the past several years have been a rollercoaster ride for our industry. Selecting HOPTEK’s Dispatch Engine solution addresses several seemingly intractable challenges, enabling us to optimize fleet utilization, increase driver satisfaction, and reduce deadhead empty miles. HOPTEK’s robust visibility platform enables us to make the best available decision, even as fleets remain dynamic, and routing and load scenarios shift constantly. We at Xtreme immediately recognized the value of HOPTEK’s strategic offering to our operation and how it would support the achievement of our goals.” Transportation and logistics are the backbone of the U.S. economy. Xtreme fuels that economic growth by delivering best-in-class operations, innovative technology solutions, and a talented workforce. The company was seeking a solution that would address very specific issues related to driver miles, route efficiency, and utilization in one platform. Achieving these goals required a unique set of capabilities. HOPTEK’s Dispatch Engine® solution closes these gaps by creating dispatchable recommendations that consider the entire fleet, at any given moment. It gets critical information to dispatchers, planners, drivers, and other stakeholders in near real-time, supercharging efficiencies and profitability. Balaji Guntur, CEO and Co-founder of HOPTEK said: “We’re excited and honored to have been selected as a long-term partner to Xtreme Trucking. Their keen eye for innovative technologies and solutions that genuinely add measurable value attests to why the industry will view Xtreme as a trend setter and leader in small to mid-size fleet tech adoption. We believe they have selected a solution that will enable them to achieve their technology goals, while at the same time supporting their efficiency mindset and profitability targets.” —Ends— About Xtreme Xtreme Trucking LLC delivers superior reefer transportation and dedicated services across the United States. With a leading view on technology and a modern truck and trailer fleet, we are an essential solutions provider for customers who value the integrity of their supply chain and require safe, and exceptional service. Moreover, Xtreme strives for leading on-time delivery and customer service, and as a technologically minded fleet, and remains deeply committed to promoting both customer and driver satisfaction. To find out how Xtreme Trucking Delivers, please visit: https://www.xtremetrucking.com/ About Kearney Kearney is a leading global management consulting firm. For nearly 100 years, we have been the trusted advisor to C-suites, government bodies, and nonprofit organizations. Our people make us who we are. Driven to be the difference between a big idea and making it happen, we help our clients break through. For more information, please visit: https://www.kearney.com/ About HOPTEK HOPTEK was founded in 2021 when global strategy and management consultancy Kearney brought its transportation and tech expertise together to help transform the trucking industry. After HOPTEK’s AI-powered system helped a leading U.S. fleet solve major operational challenges and drastically boost their performance, the company opened that technology to fleets across the U.S. With transformational technology tools such as Fleet Scanner®, Freight Finder®, and Dispatch Engine®, trucking and logistics companies can actively analyze fleet performance, identify and reduce wasteful wait times, and optimize dispatching in responsive real-time. For more information, please visit: https://www.HOPTEK.ai/ Contact Details Sean Maharaj Sean.Maharaj@hoptek.ai

September 23, 2024 09:00 AM Eastern Daylight Time

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

Join Benchmark International's Exclusive Webinar "Seller Motivation: What Goes Into the Decision to Sell?"

Benchmark International

Are you considering selling your business? Deciding when and why to sell is one of the most significant decisions you’ll ever make as a business owner. While maximizing financial proceeds is often at the forefront of these decisions, it’s essential to recognize that it’s not the only factor. Life circumstances, time with family, and other qualitative considerations can often outweigh financial gain. To help you navigate this complex process, we invite you to join our upcoming webinar: Seller Motivation: What Goes Into The Decision To Sell? Space is filling up fast, so register today! Why You Should Register Selling a business is about more than just crunching the numbers. In this exclusive webinar, you’ll gain valuable insights into the full spectrum of motivations that drive business owners to sell. Understanding these motivations can help you make a well-rounded and informed decision about your business’s future. This webinar is a must-attend for business owners contemplating the sale of their business, particularly in today’s strong but disciplined market. By attending, you’ll be better equipped to evaluate both the financial and personal factors that play a crucial role in this life-changing decision. Whether you’re focused on securing a comfortable financial future or prioritizing time with loved ones, the information presented will help you weigh these considerations effectively. Spots are limited, so don’t miss this opportunity to secure your spot. What You’ll Learn This webinar offers actionable insights into the decision-making process for business owners. Here’s what you can expect to learn: The wide range of reasons why business owners choose to sell, beyond just financial incentives How personal life events, such as family needs and future aspirations, can influence your decision A look at the current M&A market and how buyers are approaching valuations How to balance personal and financial goals using the concept of indifference curves, which help weigh non-monetary values like time with family against financial returns By attending, you’ll gain the tools to make a decision that aligns with your long-term vision—both personally and financially. Spots Are Filling Fast – Register Now! If you’re ready to gain clarity on your motivations for selling and align your decision with both your personal and financial goals, this is the webinar for you. Don’t miss out—register now and take the first step toward making a well-informed, strategic decision about the future of your business. ABOUT BENCHMARK INTERNATIONAL: Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled over $11 billion in transaction value across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network as well as the #1 Sell-side Exclusive Privately-held M&A Advisor in the World by Pitchbook and Refinitiv's Global League Tables. Contact Details Brittney Zoeller +1 813-898-2350 zoeller@benchmarkintl.com Company Website https://www.benchmarkintl.com/

September 16, 2024 09:54 AM Eastern Daylight Time

Image

MANDUKA® Launches the Dhara Yoga Apparel Collection for Women

Manduka

Manduka, creators of high performance yoga gear and the #1 choice of yoga teachers worldwide, revealed today its Dhara collection, a five-piece line of foundational yoga apparel designed for comfort, movement, and sustainability. Honoring a request from the yoga community to provide apparel they can feel good about wearing and how it is made, the Dhara collection was created with the highest standards in performance and sustainability. It’s the newest drop in the company’s plan to set the benchmark for environmentally conscious leadership in the performance wellness industry through 2025. The Dhara Collection offers a simple and easy to wear combination of premium quality, sustainability, and performance in yoga apparel. It’s designed with 88% recycled materials, a difference you can actually feel when wearing. The collection is also free from many of the harmful chemicals that can be found in other performance wear like pesticides, BPA, PFAS and formaldehyde. Technical, breathable and buttery soft, it addresses the demand for thoughtfully designed activewear that doesn’t compromise on style or functionality. “Manduka is on a path to elevate the performance and sustainability of its hardgoods and apparel lines over the next several years,” said Pamela Levine, CEO Manduka. “You will see Manduka build on its legacy of creating soulfully engineered products through usage of renewed materials, innovative manufacturing methods, and pre and post consumer waste reduction efforts. We are excited to unveil the Dhara collection as the first in this roadmap to further seamlessly integrate Manduka’s high-performance standards with a deep commitment to sustainability at a level not yet seen in the industry.” The translation of Dhara means earth with an homage to create a product with attention to the recycled materials that make up this collection. The timeless pieces are designed to offer a second skin feel that enhances your practice and doesn’t distract. The Dhara collection is made up of five ultra-soft pieces including: Dhara Bra - sleek, supportive pullover bra with four-way stretch. Features a flattering scoop neckline, low open back, and hidden underbust band. Dhara Capri Legging - high waisted fit and sleek styling makes it a versatile cropped legging with long lasting comfort. Dhara Tank - sophisticated racer back tank with a modest cropped fit. Designed with a double-knit construction with four-way stretch allows you to flow effortlessly. Dhara Legging - high waisted fit and sleek styling makes it a versatile legging with long lasting comfort. Created with a matte finish fabrication and four-way stretch ensure you move effortlessly and feel at one with your body. The Dhara collection is available in a range of colors like Avian Heather, Clay Heather, Midnight Heather, Phantom and Lions Mane and has an MSRP of $58-$90. The line will be available through www.manduka.com yoga studios and select national retailers. About Manduka Manduka was founded in 1997 with the simple idea that a better yoga mat could make a world of difference. For generations, Manduka has revolutionized the yoga space by providing purposefully crafted products that enable a more joyful practice, whatever that looks like for you. The brand's name pays homage to the Mandukasana, a challenging, thought-provoking, and freeing pose that inspires joy, laughter, and simplicity. Their loyal community of teachers, yogis and enthusiasts have been cultivated by the quality, intentionality, durability, and performance of their Mats and yoga accessories. Their unparalleled craftsmanship and sustainability efforts remain celebrated widely in wellness communities throughout the world. From their teacher-recommended PRO Series Mat to their Free Online Yoga Classes, Manduka is on a mission to inspire daily practice in all its modern forms for those seeking connection to self and humbly works in service of the community. Practice On. Website | Instagram | TikTok | YouTube Contact Details Harmonica Amber Cardullo amber@harmonica.co Company Website https://www.manduka.com

September 12, 2024 09:01 AM Eastern Daylight Time

Image

Leading Beauty Retailer Credo Beauty Debuts Private Label Skincare Line: Credo Skincare

Credo Beauty

Credo, the specialty clean beauty retail pioneer, is proud to announce the launch of its own eponymous skincare line, Credo Skincare. The specialty retailer has raised the bar introducing a benefit-driven collection of skincare products focused on the #1 skin concern gathered from clients – hydration – while continuing to challenge and elevate standards for clean and sustainable products and packaging. A cohesive easy to navigate cleanser and moisturizer system meets wanted gold standards. A decade ago, Credo disrupted an underregulated industry as a catalyst for positive change spurring a tidal wave of conscientious product and packaging innovation. Now after accruing 10 years of customer feedback, experience, and data Credo Skincare was developed according to what they found matters most. Ultimately hydration was the stand-out concern for clients. And through in-depth analysis, Credo determined the top ingredient and search terms according to what customers want from their products to deliver that and more. Through their access to the best in business partners, they created results-driven formulas packed with clinically proven actives and sustainably- minded packaging - every aspect of Credo Skincare is transparent and powerfully effective. Credo Skincare’s first collection is comprised of two cleansers ($44 each) and four moisturizers ($64 each) that service skin conditions surrounding primary concerns - dry skin, sensitivity and redness, dullness, and aging - by nourishing the skin and protecting its microbiome through today’s most powerful active combinations. Their formulations are based on key ingredient search terms and skincare concerns. As well, each product contains the transformative power of upcycled vetiver root extract, ethically harvested by a local cooperative in Haiti. Vetiver root is an antioxidant-loaded, potent wonder grass that supports the protection of the skin’s barrier for a vibrant skin tone and a nourished complexion while improving skin texture and reducing the appearance of pores and wrinkles. Credo Skincare’s goals are to provide an easy two step, effective regimen for healthy, hydrated skin that makes customers look and feel their best. Clinicals have proven 27% improvement in hydration after 24 hours, 31% improvement in hydration instantly, and an improvement in the skin barrier function instantly and after 24 hours. ● Deep Thirst Hydrating Cleanser ($44): A transformative formula to deeply cleanse while retaining moisture. ● True Timeout Calming Cleanser ($44): Designed to soothe and calm sensitive skin. ● Deep Thirst Hydrating Moisturizer ($64): Provides intense hydration with lasting effects. ● True Timeout Calming Moisturizer ($64): Helps alleviate sensitivity and redness. ● Radiance Rising Brightening Moisturizer ($64): Brightens dull skin and enhances radiance. ● Rewinder Anti-Aging Moisturizer ($64): Reduces the appearance of wrinkles and fine lines. Beyond that as a retailer, Credo Beauty continues to drive the packaging and social standards that are the hallmarks of tomorrow. Every pump and cap in the Credo Skincare collection is comprised of a first-of-its kind PCR resin, including beauty waste packaging collected in Credo Beauty stores nationwide through Pact Collective, the non-profit Credo Beauty co-founded to divert beauty packaging from landfills. ● The Credo pump was created with Pact’s NewMatter material, a mixture of hard-to-recycle material or landfill and ocean-bound plastic. ● The first run of NewMatter pumps eliminated the need for 500 kg of virgin plastic (500 kg of recycled plastic used is equivalent to 11 cubic meters of landfill space or ~2,900 gallons of space!) ● Every 38 pumps eliminate one pound of material going to the landfill or ocean. “The benefit of listening to 10 years of customers' desires and skin concerns compelled us to create this line. Years of data drove the ingredient compositions of these products so that we could exceed our customers’ expectations for efficacy. Our Credo Clean Standard is already rigorous and difficult to attain but we wanted to challenge ourselves with how our own brand could take clean innovation to new heights from full disclosure of fragrance ingredients and packaging innovation to exceeding the minimum requirements to check certain boxes, Credo Skincare raises the bar on what is possible and what can become the future baseline,” says Co-Founder and CEO Annie Jackson. Availability: Credo Skincare will be available for purchase starting September 12, 2024, at all Credo brick and mortar store locations and on www.credobeauty.com. Media Contact: press@credobeauty.com About Credo Beauty: Credo Beauty offers today’s largest clean and sustainably minded beauty assortment in North America, across color, skincare, haircare and fragrance, partnering with over 120 leading brands, such as Westman Atelier, ILIA, OSEA, True Botanicals and LolaVie. Having built the strictest and lengthy guidelines, “The Credo Clean Standard™”, customers can trust that they are purchasing the most effective, innovative products with safer ingredients with an emphasis on sustainable, natural and ethical materials. Trained makeup artists and estheticians (who are continually being educated by Credo Beauty and our brands) offer an exceptional experience both in-store and online. Visit one of the 15 brick-and-mortar store locations or www.credobeauty.com. Credo Beauty is backed by Next World Evergreen, a San Francisco-based private equity firm that invests in conscious consumer brands across sectors like clean beauty, personal care, health and wellness, sustainable lifestyle, and better-for-you food and beverage. Visit https://www.nextworldevergreen.com/ About Pact Collective: With an industry that generates over 120 billion packages every year, most ending up in landfill – they’re often too small, too flexible, or made of too many materials to be traditionally recycled. All those tiny cosmetic contraptions? They’re headed for the trash. Pact is a nonprofit collective uniting the beauty industry to take responsibility for our packaging waste and work collaboratively toward circular packaging solutions. Visit https://www.pactcollective.org/ Contact Details Amanda Smeal +1 844-692-7336 press@credobeauty.com

September 12, 2024 08:04 AM Eastern Daylight Time

Image